HoldsUp

George Church

Harvard Medical School and Massachusetts Institute of Technology

George Church, PhD, is a professor of genetics at Harvard Medical School and of health sciences and technology at Harvard and the Massachusetts Institute of Technology. His work centers on genetics, gene editing technology, and synthetic biology, and he contributed to the Human Genome Project. His published research spans topics including genome editing design, DNA synthesis, spatial transcriptomics, synthetic cellular circuits, genetic recoding, and adult genomic sequencing.

53 claims checked on air: 3 context 3 overstated 38 supported 9 unverified

What they said on air - supported

2 citing their own research

0:03:20supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Walter Gilbert's team and Fred Sanger independently published DNA sequencing methods in 1977.

"and then Wally Gilbert was my mentor as a graduate student, and his team in 1977—independently, Fred Sanger published a paper that same year." (said at 0:03:20)

Walter Gilbert (with Allan Maxam) and Frederick Sanger (with Steve Nicklen and Alan R. Coulson) independently developed and published revolutionary DNA sequencing methods in 1977. Maxam and Gilbert published their chemical cleavage sequencing method, while Sanger and colleagues published the chain-termination (dideoxy) sequencing method that same year.

0:04:28supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

The United States component of the Human Genome Project was divided into approximately 30% Department of Energy and 70% NIH funding starting in 1990 with a 15-year goal.

"And they did it kind of in teamwork with maybe 30% DOE and 70% NIH in the United States component, plus lots of international collaboration, really starting in 1990 with a 15-year goal." (said at 0:04:28)

Historical documentation of the Human Genome Project confirms that the United States effort officially began in 1990 as a coordinated partnership between the National Institutes of Health (NIH) and the Department of Energy (DOE) with an initial 15-year timeline targeted for completion by 2005. The US funding allocation across the two participating agencies closely followed a ~70% NIH to ~30% DOE division of budgetary resources alongside substantial international collaboration.

0:05:43supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

The completed draft of the Human Genome Project covered approximately 92% of the genome.

"So a lot of these shortcuts were really ill-conceived, but fortunately, we did get a decent 92% of the genome and declared victory." (said at 0:05:43)

The speaker's statement is supported by published genomic literature. Although the Human Genome Project announced completion after resolving approximately 99% of the euchromatic portion of the human genome, approximately 8% of the total genome remained unfinished or unsequenced (chiefly heterochromatin, centromeres, and repetitive regions), giving roughly 92% coverage of the total genome until the Telomere-to-Telomere consortium completed the remaining 8% in the T2T-CHM13 assembly.

0:10:50supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Sponges can produce fiber-optic-like structures, and certain biological systems synthesize ferromagnetic materials used as internal compasses.

"they can make things that are fiber-optics-like in sponges, you can make semiconductors, ferromagnetic materials that help it like a compass, there are all kinds of dichroics and gratings that generate colors" (said at 0:10:50)

The claim is well-supported by scientific literature in biomineralization and microbiology: 1. Sponges, specifically glass sponges such as *Euplectella aspergillum* and *Hyalonema sieboldi*, produce biosilica spicules that function as biological optical fibers. These spicules feature a core-clad structure with varying refractive index profiles, enabling light transmission comparable to commercial glass optical fibers. 2. Biological systems, notably magnetotactic bacteria, synthesize nanoscale crystals of ferromagnetic iron minerals (such as magnetite or greigite) within specialized organelles called magnetosomes, which align to act as an intracellular magnetic compass for orientation along geomagnetic field lines.

0:16:10supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Genomically recoding an organism by altering codons can confer broad viral resistance, which has been experimentally achieved in E. coli.

"we have a project to change the genetic code to make any cell resistant to all viruses, and we just published a paper where we think we did that. The way that it works is that all viruses, as far as we know, depend on the host genetic code... so far we've only done it in one industrial organism, E. coli" (said at 0:16:10)

The claim is supported by experimental studies in synthetic biology. Genomically recoded Escherichia coli strains—engineered by replacing specific codons (such as all UAG stop codons) across the genome and eliminating the corresponding translation factors (such as release factor 1)—demonstrated broad resistance to infection across diverse bacteriophages (including λ, M13, P1, MS2, and T7) due to the phages' dependence on the standard host translational machinery.

0:16:20supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

All known viruses rely on the host cell's genetic code and ribosomal translation machinery.

"The way that it works is that all viruses, as far as we know, depend on the host genetic code, the translation ribosomal machinery." (said at 0:16:20)

The claim accurately reflects a foundational principle of virology and molecular biology. Because viruses lack ribosomes and the enzymatic machinery necessary to synthesize proteins independently, all known viruses are obligate intracellular parasites that completely depend on the host cell's translation apparatus, ribosomes, and standard genetic decoding machinery to translate their viral mRNA into viral proteins.

0:17:20supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

In the standard genetic code, there are 64 triplet codons, and AAA codes for the amino acid lysine.

"So like AAA codes for the amino acid lysine. There's 64 of those, and if you change one, you get a new genetic code." (said at 0:17:20)

The canonical genetic code consists of 64 triplet codons composed of four nucleotide bases, which universally encode 20 canonical amino acids (with AAA specifically coding for lysine) and three stop signals. Changing codon assignments or reassigning codons generates altered genetic codes.

0:19:22supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Church's lab has achieved up to 24,000 edits in a single genome using enzymatic targeting methods.

"The maximum number of edits we've done by editing, meaning having an enzyme that's targeted to a particular place, is 24,000." (said at 0:19:22)

The claim is supported by published research from George Church's laboratory. Using targeted enzymatic methods (specifically Cas-derived base editors targeting repetitive retrotransposon sequences without causing lethal DNA double-strand breaks), the group demonstrated large-scale multiplex editing reaching up to tens of thousands of loci per cell (including ~13,200 in 293T cells, ~12,200 in human induced pluripotent stem cells, and up to ~24,000 retrotransposon loci edited across experimental conditions).

0:23:20supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Reintroducing wolves to Yellowstone National Park after 70 years altered large herbivore abundance, willow and tree growth, and beaver behavior.

"The most famous one is probably restoring the wolves to Yellowstone after 70 years. It had a typical keystone effect, had a ripple effect that was anticipated and worked out, which was they changed the abundance of large herbivores, which then changed the abundance of the willows and other trees, which changed the beavers' behavior, which built lakes, which resulted in aquaculture." (said at 0:23:20)

Ecological studies monitoring Yellowstone National Park following the 1995–1996 reintroduction of gray wolves (after an approximate 70-year absence) document a classic top-down trophic cascade. Wolf predation and behavioral displacement reduced Rocky Mountain elk density and browsing pressure, allowing riparian woody vegetation—notably willows and aspen—to recover substantially in height and biomass. This vegetation recovery facilitated an increase in beaver colonies and dam-building activity across riparian corridors, though researchers note that multicausal factors (including bison population dynamics, hydrological changes, and climate) also influence the pace and spatial variation of ecosystem recovery.

0:26:40supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Replacing the active site serine's hydroxyl oxygen with a hydrogen turns the residue into alanine and renders a serine protease completely functionless without altering its 3D structure.

"let's say you take a serine protease. It's called a serine protease because there's a very key serine right at the active site, and that serine has an oxygen that's part of the mechanism. If you change that oxygen, that hydroxyl to a hydrogen, it now becomes an alanine and it's completely functionless. But the three-dimensional structure is completely preserved." (said at 0:26:40)

The speaker accurately describes the biochemical definition and experimental manipulation of serine proteases. Chemically, serine possesses a hydroxymethyl side chain (-CH2OH); replacing the hydroxyl group (-OH) with a hydrogen atom (-H) yields a methyl group (-CH3), which is alanine. Mutating the catalytic serine residue to alanine (such as S195A in trypsin/chymotrypsin or S221A in subtilisin) abolishes the nucleophile necessary for peptide bond cleavage, reducing catalytic efficiency by millions-fold (rendering it proteolytically inactive) while preserving the native overall three-dimensional fold and substrate-binding geometry. This property is widely used in structural biology to crystallize stable enzyme-substrate or enzyme-inhibitor complexes.

0:34:20supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Smallpox is completely extinct globally as a disease in nature.

"The only thing that is truly accessible equally that I can think of offhand is—and is a biotechnology—and that is smallpox. It's completely extinct, and so you don't have to constantly be bringing out a new drug or a new vaccine that maybe not everybody can afford" (said at 0:34:20)

Global eradication of smallpox (variola virus) was achieved following an intensive global vaccination campaign and was officially certified by the World Health Organization (WHO) at the 33rd World Health Assembly in May 1980. The last naturally occurring endemic case was recorded in Somalia in 1977. Because variola virus has no known non-human animal reservoirs, the disease is entirely extinct in nature, with remaining physical viral stocks strictly restricted to designated high-containment research repositories.

0:39:15supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

The first completely recoded organism genome was engineered primarily using single-stranded DNA-annealing proteins (SSAPs) and site-specific recombinases.

"And the other evidence of its power was that the first completely recoded genome was done mostly with a combination of SSAPs and recombinases, which is also very, very precise." (said at 0:39:15)

The first genomically recoded organism (Escherichia coli strain C321.ΔA, in which all 321 known UAG stop codons were replaced with UAA) was generated primarily using Multiplex Automated Genome Engineering (MAGE) paired with Conjugative Assembly Genome Engineering (CAGE). MAGE relies on single-stranded DNA-annealing proteins (SSAPs, specifically the bacteriophage λ Red Beta protein) to iteratively integrate synthetic oligonucleotides into the replicating chromosome, followed by recombinase-mediated and conjugative assembly methods to hierarchically combine recoded genomic segments into a single fully recoded organism.

0:42:03supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Most regulatory approved gene therapies work by gene addition rather than by gene editing.

"So most gene therapies that have been approved are adding genes, and this is done typically without CRISPR. When you have a genetic disease, you're missing a gene, so you don't really want to edit necessarily; you want to add it back in." (said at 0:42:03)

The claim is accurate. Historically and currently, the vast majority of regulatory-approved gene therapies (such as Luxturna, Zolgensma, Vyjuvek, Roctavian, Hemgenix, Kymriah, and Lovo-cel) work via gene addition (also referred to as gene augmentation or transgene delivery), typically using viral vectors (e.g., AAV, lentivirus) without genome editing tools like CRISPR. While gene editing therapies (such as exagamglogene autotemcel / Casgevy, approved in late 2023) have recently begun receiving regulatory approvals, gene addition remains the predominant paradigm among approved gene therapy products.

0:42:28supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Gene therapies and palliative care for rare genetic diseases typically cost millions of dollars per person over a lifetime, whereas preconception genetic carrier screening costs in the low hundreds of dollars.

"The use of gene therapy putting in a missing gene—and, in fact, editing for that matter—for rare genetic diseases is by its nature expensive. It's millions of dollars per person over a lifetime... But the preventative medicine in this case is low hundreds of dollars just to know yourself, to know how to keep your children healthy by making preconception choices." (said at 0:42:28)

Health economic evaluations and cost-of-care analyses consistently support this contrast. Approved gene therapies and lifetime management for severe rare genetic disorders (such as spinal muscular atrophy, dystrophic epidermolysis bullosa, and other Mendelian conditions) commonly incur list prices and lifetime direct costs in the millions of dollars per patient. In contrast, expanded preconception genetic carrier screening panels assessing hundreds of conditions typically cost in the low hundreds of dollars per individual/couple and have been demonstrated to be highly cost-effective or cost-saving relative to lifetime management costs.

0:45:55supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

George Church's group engineered pig germlines with 42 to 62 simultaneous genome edits targeting porcine endogenous retroviruses and immunological genes for xenotransplantation.

"So our previous record of 62—or 42, depending on how you count it—was in pigs, and it was for tissue engineering; it was germline." (said at 0:45:55)

The claim accurately reflects published research from George Church's laboratory and collaborators. The team established multiplex CRISPR-Cas9 genome engineering in swine cells, initially demonstrating the simultaneous inactivation of 62 copies of porcine endogenous retroviruses (PERVs) to address microbiological safety hurdles for xenotransplantation tissue engineering, and later engineering pigs carrying dozens of simultaneous edits combining PERV knockouts and immunological compatibility genes.

0:46:15supportedvery lowGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

In the 1960s, a chimpanzee kidney transplant into a human patient survived and functioned for nine months.

"The idea of transplanting organs from animals to humans goes back at least to the 1960s, where a chimpanzee kidney survived for nine months in a schoolteacher who went back to teach and was normal for nine months." (said at 0:46:15)

Historical clinical records confirm that in 1963–1964, Dr. Keith Reemtsma and colleagues at Tulane University performed a series of chimpanzee-to-human kidney xenotransplants in 13 patients. One recipient, a 23-year-old schoolteacher, experienced stable graft function and returned to work for nearly nine months before dying suddenly from an electrolyte disturbance. Because this evidence comes from an uncontrolled historical case series, the certainty is rated as very low.

0:46:35supportedvery lowtheir own paperGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Non-human primates receiving germline gene-edited pig organ transplants have achieved survival times of approximately 500 to 600 days.

"synthetic biology that we do on the germline of pigs, which now made it into many preclinical primate transplant trials—pig to primate—and a few pig to human trials that are going on. Primate survival looks like around 600 days so far, and there's still a couple that are still alive at 500, 600 days." (said at 0:46:35)

Preclinical xenotransplantation studies using organs from genetically engineered porcine donors transplanted into non-human primates have demonstrated graft survival durations reaching and exceeding 500 to 600 days. For instance, baboons receiving cardiac xenografts from genetically modified pigs (with alpha 1-3 galactosyltransferase gene knockout and human transgenes) achieved graft survival up to 945 days with established prior benchmarks of 500 days. Similarly, kidney grafts from donor pigs carrying 69 genomic edits have supported long-term graft survival in cynomolgus monkeys. Because the supporting evidence comes exclusively from animal models, certainty is graded as very low.

0:50:03supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Porcine endogenous retroviruses (PERVs) are present in the germline genome of all pigs and have been shown to infect and replicate in human cells in vitro.

"The viruses that we got rid of were endogenous retroviruses, meaning they're built into the pig genome of every pig on the planet. And they have been shown to infect human cells and to replicate and go into other human cells." (said at 0:50:03)

Porcine endogenous retroviruses (PERVs) are proviral DNA sequences integrated into the germline genome of all swine breeds. In vitro studies have established that infectious PERVs released from porcine cells can productively infect cultured human cells and undergo horizontal transmission (replication and secondary infection) between human cells, motivating gene-editing efforts (such as CRISPR-Cas9 inactivation) for pig-to-human xenotransplantation.

0:50:45supportedvery lowtheir own paperGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

George Church and Luhan Yang's group published research demonstrating the use of CRISPR to target and eliminate African swine fever virus DNA.

"Anyway, as a side project, we published a paper on getting rid of African swine fever virus by making CRISPR to attack the viral DNA." (said at 0:50:45)

A 2024 study co-authored by Luhan Yang and George Church's team evaluated a multiplexed CRISPR-Cas9 system targeting nine loci across the African swine fever virus (ASFV) genome. The researchers demonstrated that targeting the viral DNA substantially suppressed ASFV replication in vitro and developed germline-edited pigs expressing the system, which delayed infection onset in some cases (though it did not ultimately confer complete survival upon challenge).

0:55:17supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

The maximum lifespan of mice is around 2 years, whereas bowhead whales can live up to approximately 200 years.

"The mice die at two years old, bowhead whales at 200, humans somewhere in between." (said at 0:55:17)

Comparative biology and mammalian longevity literature confirms that standard laboratory mice typically have an average lifespan of roughly 2 years (with maximum lifespans around 2 to 4 years depending on strain), whereas the bowhead whale (Balaena mysticetus) is recognized as the longest-lived mammal with an estimated maximum lifespan exceeding 200 years.

0:55:35supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Humans who naturally carry homozygous null mutations in both copies of the PCSK9 gene are viable, healthy, and protected against cardiovascular disease.

"It was de-risked because there were a few humans that were walking around that were basically double-null for both copies of their PCSK9 from mom and dad, and that kind of showed us that it was going to be safe and effective." (said at 0:55:35)

Human genetic studies identified rare individuals carrying biallelic inactivating (loss-of-function) mutations in PCSK9 (compound heterozygotes or homozygotes) who have undetectable circulating PCSK9, extremely low circulating LDL cholesterol levels (e.g., ~14 mg/dL), and remain healthy and fertile without apparent adverse consequences. These natural human knockouts provided key biological evidence demonstrating that lifelong profound suppression of PCSK9 is viable, well-tolerated, and protective against coronary heart disease, directly validating PCSK9 as a safe therapeutic target.

0:57:50supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Expressing the four Yamanaka transcription factors (OSKM) can reprogram somatic cells, including skin cells from an 80-year-old human, back to an embryonic-like pluripotent stem cell state capable of forming almost all body tissues.

"These are DNA-binding proteins that regulate the expression of genes, four of them, so-called Yamanaka factors, or OSKM as an abbreviation. These will very convincingly take a very old cell and turn it into a very young cell, meaning like, say, a skin cell from an 80-year-old, and it will take on many of the characteristics, most of the significant characteristics of an embryonic cell in that it can produce almost all the tissues of the body" (said at 0:57:50)

The expression of the four Yamanaka transcription factors (Oct3/4, Sox2, Klf4, and c-Myc; OSKM) successfully reprograms adult somatic cells, including dermal fibroblasts from elderly and centenarian donors, into induced pluripotent stem cells (iPSCs). These reprogrammed cells exhibit characteristics indistinguishable from human embryonic stem cells, including telomere rejuvenation, embryonic gene expression profiles, and pluripotency (the capacity to differentiate into cell types representing all three germ layers).

0:58:50supportedvery lowGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Heterochronic parabiosis and blood exchange studies show that blood from older animals induces aging biomarkers in younger animals, while blood from young animals rejuvenates older animals across multiple physiological markers.

"It's shown that what's in the blood of older and younger animals can influence one another. The older blood makes the younger ones old, and the young blood makes the older animals younger by a variety of biomarkers and disease-related things." (said at 0:58:50)

Animal studies utilizing heterochronic parabiosis (surgically connecting the circulations of young and old animals) and heterochronic blood exchange show bidirectional systemic influences on aging phenotypes. Exposure to young blood or serum restores regenerative capacity and cellular signaling in aged tissues, such as skeletal muscle satellite cells and hepatic progenitor cells. Conversely, transfusing aged blood into young animals rapidly induces cellular senescence, impairs neurogenesis, and suppresses tissue repair across multiple organ systems. Because these findings derive exclusively from preclinical animal models, certainty is graded as very low.

1:00:55supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

COVID-19 morbidity, mortality, and associated cognitive consequences increase steeply in individuals around age 60.

"even like accidental death, infectious diseases like COVID has a very—and its cognitive consequences have very steep increases at around 60 years old." (said at 1:00:55)

Large-scale epidemiological studies and meta-analyses show that COVID-19 morbidity and mortality exhibit a strong exponential relationship with age. Risk increases sharply beginning around ages 55 to 65. For example, a systematic review and meta-analysis of age-specific infection fatality rates (IFRs) demonstrated that while the estimated IFR was very low in younger populations (0.01% at age 25), it rose steeply to 0.4% by age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85.

1:01:01supportedvery lowGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

George Church's lab conducted an AAV gene therapy study in mice delivering soluble factors TGF-beta receptor, FGF21, and alpha-Klotho to reverse aging-related phenotypes.

"HOST: So I recall like one of your former publications, I forgot what year, I think it was the PNAS one, where you did gene therapy and added three transcription factors to rodents, to mice, and there was some reversal of aging or biomarkers. And it was like TGF-beta receptor and FGF21 and alpha-Klotho? GUEST1: Yeah, those three, yeah. Those were not transcription factors; those were soluble factors." (said at 1:01:01)

The claim accurately reflects a 2019 PNAS study led by Noah Davidsohn and George M. Church. The researchers delivered three protective soluble factors—fibroblast growth factor 21 (FGF21), α-Klotho, and soluble transforming growth factor-β receptor 2 (sTGFβR2)—via adeno-associated viral (AAV) vectors in mouse models, successfully treating and reversing phenotypes of multiple age-related diseases including heart failure, renal atrophy, obesity, and type 2 diabetes. Because the findings are currently limited to preclinical animal models, certainty for human application is very low.

1:01:30supportedvery lowGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Researchers demonstrated that delivering three Yamanaka transcription factors (Oct4, Sox2, and Klf4; OSK) via adeno-associated virus (AAV) can induce cellular rejuvenation in mouse models.

"But we also did a separate experiment where we took three transcription factors, O, S, and K of OSKM—separate experiments, but delivered in similar ways, adeno-associated virus." (said at 1:01:30)

In a 2020 study published in Nature (Lu et al.), researchers demonstrated that delivering Oct4, Sox2, and Klf4 (OSK) via an adeno-associated virus (AAV) vector into mouse retinal ganglion cells restored youthful DNA methylation patterns and transcriptomes, promoted axon regeneration after optic nerve injury, and reversed vision loss in aged mice. Because the evidence is derived exclusively from preclinical animal models, certainty is rated as very low.

1:02:26supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Alpha-Klotho and FGF21 are natural soluble factors, whereas the TGF-beta receptor is naturally membrane-bound and required engineering into a soluble form for systemic delivery.

"the other two are natural, alpha-Klotho and FGF21. But the TGF-beta receptor is normally membrane-bound; we made a soluble form of it. So all three of them tend to be soluble" (said at 1:02:26)

The speaker's statement accurately describes the biological characteristics of these three proteins and the engineering approach used in their published gene therapy study. Fibroblast growth factor 21 (FGF21) and αKlotho exist naturally in circulating, soluble forms. In contrast, transforming growth factor-β receptor 2 (TGFβR2) is a transmembrane cell-surface receptor; to target TGF-β signaling systemically via adeno-associated virus (AAV) gene therapy, the authors engineered a gene construct encoding a soluble extracellular domain form of the receptor (sTGFβR2). This combination gene therapy approach utilizing FGF21, αKlotho, and sTGFβR2 was demonstrated in mice by Davidsohn et al. (PNAS, 2019).

1:05:28supportedvery lowGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Church's research group evaluated 45 different single gene therapies in rodents to select the subset of three factors for combination therapy.

"we did 45 different gene therapies singly, one at a time, in rodents, mice, to find the subset of three that we wanted to test in rodents in combinations, various combinations." (said at 1:05:28)

The speaker's description matches the research program from George Church's laboratory (led by Noah Davidsohn and colleagues), which screened candidate longevity-associated genes in mouse models before publishing on the combination of three specific factors (FGF21, αKlotho, and sTGFβR2) delivered via adeno-associated virus (AAV) to treat multiple age-related diseases. Because the underlying evidence consists of preclinical animal models and internal laboratory screening assays, the certainty is graded as very low.

1:07:33supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

There is a regulatory restriction prohibiting human embryos from being cultured in vitro past 14 days of development.

"there's a ban on letting human embryos develop past 14 days in a dish" (said at 1:07:33)

The "14-day rule" is an established regulatory and bioethical policy that limits the in vitro culture of intact human embryos to a maximum of 14 days of development (or the formation of the primitive streak). While international professional guidelines (such as the 2021 update from the International Society for Stem Cell Research) have recently revisited the blanket prohibition to suggest case-by-case review, statutory and regulatory bans limiting embryo culture to 14 days remain codified in law across numerous jurisdictions worldwide.

1:16:40supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

He Jiankui targeted the CCR5 gene to confer HIV resistance in the gene-edited human embryos.

"I think was actually a pretty good choice of CCR5 and HIV resistance in He Jiankui's case." (said at 1:16:40)

The scientific literature confirms that the CCR5 gene plays a central role in HIV entry, and individuals homozygous for CCR5 loss-of-function variants (such as CCR5-Δ32) exhibit near-complete resistance to HIV infection. In 2018, researcher He Jiankui performed the first reported human germline genome editing using CRISPR to target the CCR5 gene in human embryos with the stated goal of conferring HIV resistance.

1:22:02supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Approximately 6 million babies have been born globally through in vitro fertilization.

"I think 6 million babies have been born that way, including some of my close colleagues." (said at 1:22:02)

The speaker's estimate of approximately 6 million babies born globally through in vitro fertilization (IVF) and assisted reproductive technology (ART) reflects standard global surveillance and registry estimates. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) and related global reviews estimated cumulative ART births passed 5 million around 2013, reached 6 to 8 million in subsequent years, and recent published estimates indicate the cumulative total now exceeds 8 to 10 million worldwide.

1:29:20supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Top adenoviral-vectored COVID-19 vaccines cost as little as $2 per dose, compared to typical gene therapies that cost around $2 million.

"The latest round of vaccines are kind of in a format of gene therapy and are very inexpensive compared to most gene therapies that are typically $2 million. In the case of COVID-19, they were as little as $2 for an adenoviral capsid around the double-stranded DNA for three of the top five vaccines." (said at 1:29:20)

The speaker's comparison of costs between adenoviral-vectored COVID-19 vaccines and commercial gene therapies is broadly supported by health economics literature and pharmaceutical pricing data. Recombinant adenoviral-vector platforms (delivering double-stranded DNA encoding the viral antigen in an adenoviral capsid, such as Oxford/AstraZeneca's ChAdOx1-S) were manufactured at massive scale and distributed under not-for-profit or advance-market agreements for roughly $2 to $4 per dose in several markets. In contrast, approved in vivo and ex vivo cell and gene therapies (such as those for rare genetic conditions and hemoglobinopathies) typically carry wholesale acquisition prices between $1 million and $3 million per treatment course (frequently modeled at a standard $2 million benchmark).

1:30:27supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Preconception genetic screening and mate-selection programs in specific populations have virtually eliminated certain severe inherited genetic diseases.

"So there's a tiny sector of society that practices preconception decision-making, and those have almost eliminated major, serious genetic diseases." (said at 1:30:27)

Preconception carrier screening and mate-selection programs (most notably Dor Yeshorim and community screening programs within Ashkenazi Jewish populations) have achieved near-elimination of severe recessive disorders such as Tay-Sachs disease within those participating communities. Published literature frequently highlights the Jewish community's population-based carrier screening as a successful paradigm demonstrating the prevention of severe Mendelian genetic diseases through preconception decision-making.

1:37:15supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

CCR5 knockout or null mutations can increase susceptibility to West Nile virus and certain influenza strains.

"So people will say, "Well, CCR5 is not a good idea for germline, and maybe it's not even a good idea for somatic because it could make you sensitive to West Nile or to certain influenza."" (said at 1:37:15)

Human genetic association studies and meta-analyses support that CCR5 deficiency (such as the CCR5-Δ32 null variant or knockout) is associated with an increased risk of severe, symptomatic West Nile virus disease and increased severity/mortality in certain influenza infections. A systematic review and meta-analysis confirmed that CCR5 variation is significantly associated with symptomatic West Nile virus disease (meta-OR = 1.29), and observational studies have linked CCR5-Δ32 with increased early/late clinical manifestations of West Nile virus as well as higher mortality during severe influenza infection.

1:42:18supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Only female mosquitoes bite and consume blood, whereas male mosquitoes feed on nectar and act as pollinators.

"The males are pollinators, uh, females, um, are the bloodsuckers in this case." (said at 1:42:18)

Entomological research confirms that female mosquitoes require blood meals for egg production (hematophagy), whereas male mosquitoes lack mouthparts capable of piercing skin and feed exclusively on plant nectar, honeydew, and other sugar sources. While foraging on floral nectar, male (as well as female) mosquitoes visit flowers and can serve as pollinators for various plant species.

1:43:24supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Mosquitofish do not depend on mosquitoes as an obligatory food source.

"Um, but, uh, even mosquitofish do not depend on mosquitoes." (said at 1:43:24)

The claim is supported by dietary studies of mosquitofish (Gambusia affinis and Gambusia holbrooki). Mosquitofish are generalist and opportunistic omnivores whose diet varies widely according to local prey availability, consisting of microcrustaceans (such as cladocerans and copepods), terrestrial insects, detritus, aquatic bugs, and other small invertebrates. They do not rely obligatorily on mosquito larvae or adults for survival.

1:47:25supportedhighGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

A Lyme disease vaccine has remained in continuous veterinary use for dogs after the human vaccine was withdrawn.

"It's been in use in dogs several the whole time. It's it's one of these cases where dogs get better medical care than humans do, because, you know, we love our dogs and apparently we don't care about ourselves." (said at 1:47:25)

The claim is supported by veterinary and medical literature. Following the withdrawal of the only licensed human Lyme disease vaccine (LYMErix) in the early 2000s due to safety controversies and declining demand, canine Lyme disease vaccines (including whole-cell bacterins and recombinant outer surface protein formulations) have remained continuously available and approved for veterinary use in dogs.

1:50:20supportedmoderateGeorge Church, PhD: Rewriting Genomes to Eradicate Disease a

Eating a meal promotes sleepiness in many individuals.

"the tendency to go to sleep after a meal, which is true for many people, it's especially true for me" (said at 1:50:20)

Postprandial somnolence (sleepiness after eating) is a well-documented physiological response. Controlled trials comparing meal ingestion to sham feeding have confirmed that eating a solid meal significantly reduces objective sleep onset latency (the time it takes to fall asleep). Multiple physiological factors, including meal composition, gastrointestinal signaling, and inflammatory cytokines (such as IL-1), contribute to post-meal fatigue and sleepiness.

Fact-checked episodes

Publications